DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 569-572

  Lencz, Todd ^a,c,d   Robinson, Delbert G ^a,c,d   Napolitano, Barbara ^b   Sevy, Serge ^a,c,d   Kane, John M ^a,c,d   Goldman, David ^e   Malhotra, Anil K ^a,c,d  

^a Center for Psychiatric Neuroscience   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

antipsychotic; dopamine; DRD2; pharmacogenetics; weight gain

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 77955919157     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ca24b     Document Type: Article

References (17)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272.
2. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodŕ?guez-Sánchez JM, Pérez-Iglesias R, Vázquez-Barquero JL. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22:547-562.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
4. Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 2009; 11:405-415.
5. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090.
6. Zhang ZJ, Yao ZJ, Zhang XB, Chen JF, Sun J, Yao H, Hou G, Zhang XB. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin 2003; 24:235-240.
7. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69:1416-1422.
8. 2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6:577-582.
9. 2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4:290-296.
10. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163:529-531.
11. Zhang J, Lencz T, Malhotra AK. Dopamine D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010. doi:10.1176/appi.ajp.2009.09040598. [Epub ahead of print]
12. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12:707-747.
13. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006; 163:2096-2102.
14. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995; 3:515S-523S.
15. Cope MB, Li X, Jumbo-Lucioni P, DiCostanzo CA, Jamison WG, Kesterson RA, et al. Risperidone alters food intake, core body temperature, and locomotor activity in mice. Physiol Behav 2009; 96:457-463.
16. Thanos PK, Michaelides M, Piyis YK, Wang GJ, Volkow ND. Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in-vivo muPET imaging ([11C] raclopride) and in-vitro ([3H] spiperone) autoradiography. Synapse 2008; 62:50-61.
17. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, et al. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage 2008; 42:1537-1543.